Please enable JavaScript to continue using this application.

Compare $FATE vs $IMRX | Chartloom

Compare

$FATE vs $IMRX

Fate Therapeutics Inc · Immuneering Corp

FATE

Fate Therapeutics Inc

IMRX

Immuneering Corp

Compare $FATE vs $IMRX

Comparing Fate Therapeutics Inc and Immuneering Corp

FATEFate Therapeutics Inc

IMRXImmuneering Corp

FATEFate Therapeutics Inc

Market cap

$254M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

54.34x

Rev growth (TTM)

-23.4%

YTD performance

120.2%

52W performance

44.4%

FCF yield

-41.6%

IMRXImmuneering Corp

Market cap

$255M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-40.5%

52W performance

-39.4%

FCF yield

-22.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

FATE

IMRX

Detailed metrics comparison

FATE

Fate Therapeutics Inc

IMRX

Immuneering Corp

Market Cap

FATE$254M

IMRX$255M

Enterprise Value

FATE$234M

IMRX$214M

Price

FATE$2.18

IMRX$3.94

P/E Ratio

FATEN/A

IMRXN/A

P/S Ratio

FATE39.15x

IMRX526.64x

EV/Sales

FATE35.98x

IMRX443.99x

EV/EBITDA

FATE0.00x

IMRX0.00x

P/B Ratio

FATE1.81x

IMRX1.38x

P/FCF Ratio

FATEN/A

IMRXN/A

EV/FCF

FATE-2.21x

IMRX-3.75x

PEG Ratio

FATEN/A

IMRXN/A

Forward P/E (NTM)

FATEN/A

IMRXN/A

Forward P/S (NTM)

FATE54.34x

IMRXN/A

Revenue (TTM)

FATE$6M

IMRX$0

Revenue Growth (YoY)

FATE-23.4%

IMRXN/A

Forward Rev Growth

FATE-17.6%

IMRX100.5%

Gross Margin (TTM)

FATE0.0%

IMRX28.0%

Operating Margin (TTM)

FATE0.0%

IMRX0.0%

EBITDA Margin (TTM)

FATE-1873.4%

IMRX0.0%

Net Margin (TTM)

FATE-1941.1%

IMRX0.0%

FCF Margin (TTM)

FATE-1627.8%

IMRXN/A

Net Income (TTM)

FATE$-126M

IMRX$-57M

FCF (TTM)

FATE$-106M

IMRX$-57M

EPS (TTM)

FATE-$1.05

IMRX-$0.89

ROE (TTM)

FATE-6508.0%

IMRX-2715.0%

ROA (TTM)

FATE-4173.0%

IMRX-2574.0%

ROIC (TTM)

FATE-6174.0%

IMRX-2715.0%

Cash

FATE$32M

IMRX$41M

Debt

FATE$12M

IMRX$0

Net Cash/Debt

FATE$21M

IMRX$41M

Current Ratio (TTM)

FATE4.85x

IMRX19.47x

Quick Ratio (TTM)

FATE4.74x

IMRX18.47x

Debt/Equity (TTM)

FATE0.08x

IMRX0.00x

Debt/Assets (TTM)

FATE0.0%

IMRX0.0%

Interest Coverage (TTM)

FATEN/A

IMRXN/A

Net Debt/EBITDA (TTM)

FATE0.00x

IMRX0.00x

Beta

FATE2.67

IMRX0.34

52W Performance

FATE44.4%

IMRX-39.4%

YTD Performance

FATE120.2%

IMRX-40.5%

% from 52W High

FATE-32.5%

IMRX-53.5%

% from 52W Low

FATE129.5%

IMRX9.4%

Asset Turnover (TTM)

FATE0.02x

IMRX0.00x

FCF Yield (TTM)

FATE-41.6%

IMRX-22.4%

Earnings Yield (TTM)

FATE-49.6%

IMRX-22.5%

Dividend Yield (TTM)

FATEN/A

IMRXN/A

Rule of 40

FATE-1,651.1

IMRX0.0

EV/GP/RG

FATEN/A

IMRXN/A

Ticker research

View FATE research View IMRX research

Metric	FATE Fate Therapeutics Inc	IMRX Immuneering Corp
Market & Valuation
Market Cap	$254M	$255M
Enterprise Value	$234M	$214M
Price	$2.18	$3.94
P/E Ratio	N/A	N/A
P/S Ratio	39.15x	526.64x
EV/Sales	35.98x	443.99x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.81x	1.38x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.21x	-3.75x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	54.34x	N/A
Revenue & Growth
Revenue (TTM)	$6M	$0
Revenue Growth (YoY)	-23.4%	N/A
Forward Rev Growth	-17.6%	100.5%
Profitability
Gross Margin (TTM)	0.0%	28.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1873.4%	0.0%
Net Margin (TTM)	-1941.1%	0.0%
FCF Margin (TTM)	-1627.8%	N/A
Net Income (TTM)	$-126M	$-57M
FCF (TTM)	$-106M	$-57M
EPS (TTM)	-$1.05	-$0.89
ROE (TTM)	-6508.0%	-2715.0%
ROA (TTM)	-4173.0%	-2574.0%
ROIC (TTM)	-6174.0%	-2715.0%
Financial Health
Cash	$32M	$41M
Debt	$12M	$0
Net Cash/Debt	$21M	$41M
Current Ratio (TTM)	4.85x	19.47x
Quick Ratio (TTM)	4.74x	18.47x
Debt/Equity (TTM)	0.08x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.67	0.34
52W Performance	44.4%	-39.4%
YTD Performance	120.2%	-40.5%
% from 52W High	-32.5%	-53.5%
% from 52W Low	129.5%	9.4%
Efficiency & Yields
Asset Turnover (TTM)	0.02x	0.00x
FCF Yield (TTM)	-41.6%	-22.4%
Earnings Yield (TTM)	-49.6%	-22.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,651.1	0.0
EV/GP/RG	N/A	N/A
Ticker research	View FATE research	View IMRX research

Valuation

P/S Ratio

FATE

39.15x

IMRX

526.64x

EV/FCF

IMRX

-3.75x

FATE

-2.21x

Growth & revenue

Revenue Growth TTM

FATE

-23.4%

Forward Revenue Growth

IMRX

100.5%

FATE

-17.6%

Profitability & performance

Gross Margin

IMRX

28.0%

FATE

0.0%

ROE

IMRX

-2715.0%

FATE

-6508.0%

FCF Yield %

IMRX

-22.4%

FATE

-41.6%

52-Week Performance

FATE

44.4%

IMRX

-39.4%

Detailed metrics comparison

FATE

Fate Therapeutics Inc

IMRX

Immuneering Corp

Market Cap

FATE$254M

IMRX$255M

Enterprise Value

FATE$234M

IMRX$214M

Price

FATE$2.18

IMRX$3.94

P/E Ratio

FATEN/A

IMRXN/A

P/S Ratio

FATE39.15x

IMRX526.64x

EV/Sales

FATE35.98x

IMRX443.99x

EV/EBITDA

FATE0.00x

IMRX0.00x

P/B Ratio

FATE1.81x

IMRX1.38x

P/FCF Ratio

FATEN/A

IMRXN/A

EV/FCF

FATE-2.21x

IMRX-3.75x

PEG Ratio

FATEN/A

IMRXN/A

Forward P/E (NTM)

FATEN/A

IMRXN/A

Forward P/S (NTM)

FATE54.34x

IMRXN/A

Revenue (TTM)

FATE$6M

IMRX$0

Revenue Growth (YoY)

FATE-23.4%

IMRXN/A

Forward Rev Growth

FATE-17.6%

IMRX100.5%

Gross Margin (TTM)

FATE0.0%

IMRX28.0%

Operating Margin (TTM)

FATE0.0%

IMRX0.0%

EBITDA Margin (TTM)

FATE-1873.4%

IMRX0.0%

Net Margin (TTM)

FATE-1941.1%

IMRX0.0%

FCF Margin (TTM)

FATE-1627.8%

IMRXN/A

Net Income (TTM)

FATE$-126M

IMRX$-57M

FCF (TTM)

FATE$-106M

IMRX$-57M

EPS (TTM)

FATE-$1.05

IMRX-$0.89

ROE (TTM)

FATE-6508.0%

IMRX-2715.0%

ROA (TTM)

FATE-4173.0%

IMRX-2574.0%

ROIC (TTM)

FATE-6174.0%

IMRX-2715.0%

Cash

FATE$32M

IMRX$41M

Debt

FATE$12M

IMRX$0

Net Cash/Debt

FATE$21M

IMRX$41M

Current Ratio (TTM)

FATE4.85x

IMRX19.47x

Quick Ratio (TTM)

FATE4.74x

IMRX18.47x

Debt/Equity (TTM)

FATE0.08x

IMRX0.00x

Debt/Assets (TTM)

FATE0.0%

IMRX0.0%

Interest Coverage (TTM)

FATEN/A

IMRXN/A

Net Debt/EBITDA (TTM)

FATE0.00x

IMRX0.00x

Beta

FATE2.67

IMRX0.34

52W Performance

FATE44.4%

IMRX-39.4%

YTD Performance

FATE120.2%

IMRX-40.5%

% from 52W High

FATE-32.5%

IMRX-53.5%

% from 52W Low

FATE129.5%

IMRX9.4%

Asset Turnover (TTM)

FATE0.02x

IMRX0.00x

FCF Yield (TTM)

FATE-41.6%

IMRX-22.4%

Earnings Yield (TTM)

FATE-49.6%

IMRX-22.5%

Dividend Yield (TTM)

FATEN/A

IMRXN/A

Rule of 40

FATE-1,651.1

IMRX0.0

EV/GP/RG

FATEN/A

IMRXN/A

Ticker research

View FATE research View IMRX research

Metric	FATE Fate Therapeutics Inc	IMRX Immuneering Corp
Market & Valuation
Market Cap	$254M	$255M
Enterprise Value	$234M	$214M
Price	$2.18	$3.94
P/E Ratio	N/A	N/A
P/S Ratio	39.15x	526.64x
EV/Sales	35.98x	443.99x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.81x	1.38x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.21x	-3.75x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	54.34x	N/A
Revenue & Growth
Revenue (TTM)	$6M	$0
Revenue Growth (YoY)	-23.4%	N/A
Forward Rev Growth	-17.6%	100.5%
Profitability
Gross Margin (TTM)	0.0%	28.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1873.4%	0.0%
Net Margin (TTM)	-1941.1%	0.0%
FCF Margin (TTM)	-1627.8%	N/A
Net Income (TTM)	$-126M	$-57M
FCF (TTM)	$-106M	$-57M
EPS (TTM)	-$1.05	-$0.89
ROE (TTM)	-6508.0%	-2715.0%
ROA (TTM)	-4173.0%	-2574.0%
ROIC (TTM)	-6174.0%	-2715.0%
Financial Health
Cash	$32M	$41M
Debt	$12M	$0
Net Cash/Debt	$21M	$41M
Current Ratio (TTM)	4.85x	19.47x
Quick Ratio (TTM)	4.74x	18.47x
Debt/Equity (TTM)	0.08x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.67	0.34
52W Performance	44.4%	-39.4%
YTD Performance	120.2%	-40.5%
% from 52W High	-32.5%	-53.5%
% from 52W Low	129.5%	9.4%
Efficiency & Yields
Asset Turnover (TTM)	0.02x	0.00x
FCF Yield (TTM)	-41.6%	-22.4%
Earnings Yield (TTM)	-49.6%	-22.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,651.1	0.0
EV/GP/RG	N/A	N/A
Ticker research	View FATE research	View IMRX research